Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT04491383
NCT04491383Active, not recruitingPhase 2

Tocotrienols in Parkinson's Disease (PD): A Pilot, Randomised, Placebo-controlled Trial

National Neuroscience Institute2 sites in 1 country100 target enrollmentStarted: April 1, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Active, not recruiting
Enrollment
100
Locations
2
Primary Endpoint
Mean change from Baseline to Week 104 in Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Score
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

A study using Parkinson's disease animal model, transgenic fruit flies, demonstrated the potential of using tocotrienols (HOV-12020) as a therapeutic agent for delaying Parkinsonian motor dysfunctions. The proposed study aims to enrol 100 PD patients in a randomized placebo-controlled trial to investigate the effects of tocotrienols (HOV-12020) in motor and non-motor outcomes. Patients will be given oral tocotrienols (400mg/day) or placebo for 104 weeks. They will be assessed using the standard assessments scales in PD at baseline, Week 52 and Week 104. Neuropsychological evaluation will also be completed at these intervals to monitor progression of cognitive impairment (if any). Additional PD staging using MDSUPDRS (Part III), Hoehn & Yahr (H&Y) will be conducted at Week 26 and week 78. Blood samples will be collected to evaluate PD biomarkers and for safety monitoring (liver function, renal function and hematology).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description

This is a double-blind clinical trial.

Eligibility Criteria

Ages
40 Years to 90 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Men or women aged between 40 - 90 years (inclusive).
  • •Able to provide written informed consent and able to comply with study protocol.
  • •Idiopathic PD of more than 1 years duration from diagnosis. The diagnosis must be confirmed by presence of bradykinesia and at least 1 other cardinal sign (resting tremor, rigidity), without any other known or suspected cause of parkinsonism.
  • •Hoehn & Yahr => 2 with treatment.
  • •Patients on PD medication(s) e.g. levodopa, dopamine agonists, amantadine and/or Monoamine oxidase (MAO)-B inhibitors, must be on stable dose, for at least 30 days prior to screening. Medication and dose adjustments are allowed but must be documented.
  • •Patients on anti-depressant or anxiolytic medication must be on stable dose for at least 90 days prior to screening.
  • •The patient is willing to abstain from Vitamin E supplements (tocopherols and tocotrienols) and other dietary supplements which contain Vitamin E (tocopherols and tocotrienols) up to 14 days before baseline visit, and throughout the clinical study, unless prescribed by their physician for medical reasons.

Exclusion Criteria

  • •Any other neurodegenerative disorder, such as Alzheimer's disease, Huntington's disease, or Creutzfeldt - Jakob disease.
  • •Current, clinically-significant hematological, cardiac, pulmonary, metabolic, neurologic or psychiatric disorders, uncontrolled seizures, untreated hypertension, disorders increasing risk of bleeding (Hemophilia), or any other significant active medical condition which, in the Investigator's opinion, would impact participation in this study.
  • •History of psychotic symptoms requiring treatment with a neuroleptic medication within the past 12 months.
  • •History of surgical or invasive intervention for PD (pallidotomy, thalamotomy, deep brain stimulation, etc.)
  • •Medical history indicating drug-induced parkinsonism (e.g., metoclopramide, flunarizine), metabolic identified neurogenetic disorders (e.g., Wilson's disease), encephalitis, or other atypical Parkinsonian syndromes (e.g., progressive supranuclear palsy, multiple system atrophy).
  • •History of myocardial infarction within 3 months prior to Screening, or current active angina pectoris, or symptomatic heart failure.
  • •Known liver disease or liver enzymes (AST, ALT) more than 5 times upper limit normal within 1 month of screening and enrolment.
  • •eGFR <60 within 1 month of screening and enrolment.
  • •Current participation in another investigational interventional study.

Arms & Interventions

Tocovid Suprabio (HOV-12020)

Experimental

200mg, twice 1 day, 12 months

Intervention: Tocovid Suprabio (HOV-12020) (Drug)

Placebo

Placebo Comparator

200mg, twice 1 day, 12 months

Intervention: Placebo (Other)

Outcomes

Primary Outcomes

Mean change from Baseline to Week 104 in Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Score

Time Frame: 104 weeks

Score range is 0 to 199, with severity increasing with higher scores.

Secondary Outcomes

  • Mean change from baseline to week 104 in disease severity(104 weeks)
  • Mean change from baseline to week 104 in individual cognitive domain z scores on comprehensive neuropsychological testing mean score change from baseline to week 104 in the MDS-UPDRS score for total score(104 weeks)
  • Mean change from Baseline to Week 104 in quality of life, as measured by the Parkinson's Disease Questionnaire (PDQ-39)(104 weeks)
  • Difference proportion of patients with change from Baseline to Week 104, above or equal to the minimal clinically important difference (MCID) of the motor score, as measured by Part II and III subscales of MDS-UPDRS.(104 weeks)
  • Mean change in levels of blood-based biomarkers (including total antioxidant status TAS, oxidative stress biomarkers and αsynuclein).(104 weeks)
  • Between treatment difference of type and incidence of Adverse Events (AEs) and Serious AEs (SAEs)(104 weeks)
  • Mean score change from Baseline to Week 104 in the MDS-UPDRS Part II scale(104 weeks)
  • Mean score change from Baseline to Week 104 in the Schwab and England Activities of Daily Living (SE-ADL) scale.(104 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 3
Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes MellitusCognitive ImpairmentDiabetic Neuropathy
NCT01973400Universiti Sains Malaysia300
Completed
Phase 2
Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's DiseaseParkinson Disease
NCT05781711Tanta University60
Completed
Phase 2
A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's DiseaseParkinson's Disease
NCT01539837Imperial College London22
Active, not recruiting
Not Applicable
Parkinson's Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.Parkinson Disease
NCT03981055Spaulding Rehabilitation Hospital40
Completed
Not Applicable
Catechol Thioethers in Parkinson's DiseaseParkinson's Disease
NCT00042692National Institute of Environmental Health Sciences (NIEHS)20